Company intelligence / Profile preview

Santa Maria Biotherapeutics, Inc.

California, United Statesatarabio.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Santa Maria Biotherapeutics developed STM 434, an activin type IIB receptor Fc fusion protein. A Phase I/1b clinical trial evaluated its safety and pharmacokinetics alone or with liposomal doxorubicin in patients with ovarian cancer or other advanced solid tumors. The company’s approach aimed to reduce tumor burden and mitigate cachexia. Clinical results are not detailed in public sources; the program was later subsumed under Atara Biotherapeutics’ pipeline.

Therapeutic areas: Oncology
Modalities: Fc fusion proteins
Industry: Biotech

Drug pipeline

2 assets

PINTA 745

Phase 2

Indications: Protein-energy wasting, End-stage renal disease

1 more asset in the full pipeline.

Request access →

Partnerships

AmgenKleiner Perkins Caufield & Byers

Beyond the preview

Go deeper on Santa Maria Biotherapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Santa Maria Biotherapeutics, Inc..

Explore the full profile